{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:52:37Z","timestamp":1790787157032,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bioethics Committee","award":["BNW\/NWN\/0052\/KB\/128\/25"],"award-info":[{"award-number":["BNW\/NWN\/0052\/KB\/128\/25"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Our study aimed to assess the anatomical changes in the retina, including the assessment of the reduction of diabetic macular edema (DME) on optical coherence tomography (OCT) and the improvement of retinal microvascular parameters, defined by the reduction of nonperfusion areas on OCT angiography (OCTA) after intravitreal injections of 6 mg faricimab, an anti-VEGF drug used in the treatment of DME. The study included twenty-two patients aged between 61 and 74 years, each of whom received four loading doses of 6 mg faricimab at 1-month intervals, as described in the summary of product characteristics. Hemodynamic parameters were analyzed by OCT angiography before the first intravitreal injection of faricimab and one month after each subsequent injection. The following parameters were analyzed: non-perfusion area (NPA), superficial capillary plexus (SCP) and deep capillary plexus (DCP), outer retinal flow area (ORFA), choriocapillaris flow area (CCFA) and foveal avascular zone (FAZ). Despite differences in the magnitude of improvement and time to improvement from the start of treatment with intravitreal injections of 6 mg faricimab, reductions in DME and improvements in OCTA parameters resulted in increased retinal blood flow and better visual acuity.<\/jats:p>","DOI":"10.3390\/pharmaceutics17070858","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:46:12Z","timestamp":1751438772000},"page":"858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3596-7970","authenticated-orcid":false,"given":"Dorota","family":"\u015apiewak","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Prof. K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"},{"name":"Clinical Ophthalmology Center Okolux, 40-754 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Drzyzga","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Prof. K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"},{"name":"Clinical Ophthalmology Center Okolux, 40-754 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Dorecka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Prof. K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"},{"name":"Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-287 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Witek","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Prof. K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Wygl\u0119dowska-Promie\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Prof. K. Gibi\u0144ski University Clinical Center, Medical University of Silesia, 40-514 Katowice, Poland"},{"name":"Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-287 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gomulka, K., and Ruta, M. (2023). The Role of Inflammation and Therapeutic Concepts in Diabetic Retinopathy\u2014A Short Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021024"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jdi.13480","article-title":"Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy","volume":"12","author":"Lin","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_4","first-page":"75","article-title":"Diabetic retinopathy: Early diagnosis and effective treatment","volume":"107","author":"Kollias","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Spiewak, D., Drzyzga, L., Dorecka, M., and Wygledowska-Promienska, D. (2024). Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD. J. Clin. Med., 13.","DOI":"10.3390\/jcm13144227"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dervenis, N., Dervenis, P., and Agorogiannis, E. (2024). Neovascular age-related macular degeneration: Disease pathogenesis and current state of molecular biomarkers predicting treatment response\u2014A scoping review. BMJ Open Ophthalmol., 9.","DOI":"10.1136\/bmjophth-2023-001516"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Khan, M., Aziz, A.A., Shafi, N.A., Abbas, T., and Khanani, A.M. (2020). Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells, 9.","DOI":"10.3390\/cells9081869"},{"key":"ref_8","first-page":"505","article-title":"Diabetic Macular Edema","volume":"32","author":"Gundogan","year":"2016","journal-title":"Pak. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lazar, A.S., Stanca, H.T., Tabacaru, B., Danielescu, C., Munteanu, M., and Stanca, S. (2023). Quantitative Parameters Relevant for Diabetic Macular Edema Evaluation by Optical Coherence Tomography Angiography. Medicina, 59.","DOI":"10.3390\/medicina59061120"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Massengill, M.T., Cubillos, S., Sheth, N., Sethi, A., and Lim, J.I. (2024). Response of Diabetic Macular Edema to Anti-VEGF Medications Correlates with Improvement in Macular Vessel Architecture Measured with OCT Angiography. Ophthalmol. Sci., 4.","DOI":"10.1016\/j.xops.2024.100478"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ferro Desideri, L., Traverso, C.E., Nicolo, M., and Munk, M.R. (2023). Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051413"},{"key":"ref_12","unstructured":"(2022, September 15). Annex I: Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/2474126416682569","article-title":"Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection","volume":"1","author":"Shah","year":"2017","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","article-title":"Switching between anti-VEGF agents in the management of refractory diabetic macular edema: A systematic review","volume":"67","author":"Madjedi","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oret.2022.10.008","article-title":"Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema: A Meta-Analysis","volume":"7","author":"Patil","year":"2023","journal-title":"Ophthalmol. Retin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ophtha.2016.07.010","article-title":"Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response","volume":"123","author":"Lee","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Suciu, C.I., Suciu, V.I., and Nicoara, S.D. (2020). Optical Coherence Tomography (Angiography) Biomarkers in the Assessment and Monitoring of Diabetic Macular Edema. J. Diabetes Res., 2020.","DOI":"10.1155\/2020\/6655021"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"OCT362","DOI":"10.1167\/iovs.15-18904","article-title":"Quantifying Microvascular Density and Morphology in Diabetic Retinopathy Using Spectral-Domain Optical Coherence Tomography Angiography","volume":"57","author":"Kim","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajo.2015.04.021","article-title":"Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study","volume":"160","author":"Ishibazawa","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"BIO307","DOI":"10.1167\/iovs.17-21787","article-title":"Quantifying Microvascular Abnormalities with Increasing Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography","volume":"58","author":"Nesper","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s10792-018-1013-0","article-title":"Macular vessels density in diabetic retinopathy: Quantitative assessment using optical coherence tomography angiography","volume":"39","author":"AttaAllah","year":"2019","journal-title":"Int. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"OCT348","DOI":"10.1167\/iovs.15-18782","article-title":"New Insights Into Microaneurysms in the Deep Capillary Plexus Detected by Optical Coherence Tomography Angiography in Diabetic Macular Edema","volume":"57","author":"Hasegawa","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"H1696","DOI":"10.1152\/ajpheart.00221.2007","article-title":"Oxygen distribution and consumption in the macaque retina","volume":"293","author":"Birol","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Braham, I.Z., Kaouel, H., Boukari, M., Ammous, I., Errais, K., Boussen, I.M., and Zhioua, R. (2022). Optical coherence tomography angiography analysis of microvascular abnormalities and vessel density in treatment-naive eyes with diabetic macular edema. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02632-3"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4274\/tjo.galenos.2020.81592","article-title":"Vessel Density Changes on Optical Coherence Tomography Angiography after Vascular Endothelial Growth Factor Inhibitor Treatment for Diabetic Macular Edema","volume":"50","author":"Cheong","year":"2020","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.16-20579","article-title":"Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes with Diabetic Macular Edema and Retinal Vein Occlusion","volume":"58","author":"Iafe","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41433-021-01750-4","article-title":"Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy","volume":"36","author":"Chatziralli","year":"2022","journal-title":"Eye"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/OPTH.S118807","article-title":"Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections","volume":"11","author":"Levin","year":"2017","journal-title":"Clin. Ophthalmol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/7\/858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:43Z","timestamp":1760032903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/7\/858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["pharmaceutics17070858"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17070858","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}